Advertisement
A live web cast and recording of the presentation will be available for 30days following the presentation on AtriCure's Investor Relations page atwww.atricure.com.
Advertisement
About AtriCure, Inc.
AtriCure, Inc. is a medical device company focused on developing,manufacturing and selling innovative cardiac surgical devices designed tocreate precise lesions, or scars, in cardiac, or heart, tissues. Medicaljournals have described the adoption by leading cardiothoracic surgeons of theAtriCure Isolator(R) bipolar ablation clamps as a treatment alternative duringopen-heart surgical procedures to create lesions in cardiac tissue to blockthe abnormal electrical impulses that cause atrial fibrillation, or AF, arapid, irregular quivering of the upper chambers of the heart. Additionally,leading cardiothoracic surgeons have described the AtriCure Isolator(R) clampsas a promising treatment alternative for patients who may be candidates forsole-therapy minimally invasive procedures. AF affects more than 2.5 millionAmericans and predisposes them to a five-fold increased risk of stroke.
The FDA has cleared the AtriCure Isolator(R) bipolar ablation system,including the new Isolator Synergy(TM) ablation clamps, for the ablation, ordestruction, of soft tissues in general and cardiac related surgicalprocedures, but to date has not cleared or approved the system for thetreatment of AF. The FDA has cleared the AtriCure multifunctional bipolar Penfor the ablation of cardiac tissue and for temporary pacing, sensing,stimulating and recording during the evaluation of cardiac arrhythmias, butthe multifunctional bipolar Pen has not been approved for the treatment of AF.Contact: AtriCure, Inc. Julie A. Piton Vice President and Chief Financial Officer (513) 755-4561 [email protected]
SOURCE AtriCure, Inc.